Kolexia
Roussel Murielle Hématologie
Roussel Murielle
Hématologie
Hôpital Dupuytren
Limoges, France
295 Activités
104 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Amyloïdose Amylose à chaine légère d'immunoglobuline Récidive tumorale locale Maladie résiduelle Aberrations des chromosomes Translocation génétique Lymphomes

Collaborateurs

Voir plus
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Attal Michel
Attal Michel
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Voir plus
B3TSI
65 collaboration(s)
Dernière en 2023
A+A
36 collaboration(s)
Dernière en 2023
IQVIA
28 collaboration(s)
Dernière en 2023
Janssen
18 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Essai Clinique (BMS)   20 mars 2024
SUCCESSOR-1: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Essai Clinique (Celgene)   07 mars 2024
Myélome du jeune et du très jeune patient : actualités
Edimark   28 février 2024
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series.
Blood   14 décembre 2023
Monitoring of Systemic Light-Chain Amyloidosis Patients Using Mass Spectrometry (M-inSight) in Serum
65th ASH Annual Meeting Abstracts   02 novembre 2023
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.
Blood cancer journal   26 octobre 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
L'expert français... - Association française contre l'amylose | Facebook
Facebook   09 juin 2023
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica   01 mai 2023